Uremic toxins inhibit renal metabolic capacity through interference with glucuronidation and mitochondrial respiration

H.A.M. Mutsaers a,b, M.J.G. Wilmer a, D. Reijnders a, J. Jansen b, P.H.H. van den Broek a, M. Forink c, E. Schepers d, G. Glorieux e, R. Vanholder e, L.P. van den Heuvel d,f, J.G. Hoenderop b, R. Masereeuw a,*

a Department of Pharmacology and Toxicology, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands
b Department of Physiology, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands
c Department of Biochemistry, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands
d Department of Pediatrics, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands
e Department of Pediatrics, Catholic University Leuven, Leuven, Belgium
f Department of Pediatrics, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands

ARTICLE INFO

Article history:
Received 16 July 2012
Received in revised form 10 September 2012
Accepted 17 September 2012
Available online 24 September 2012

Keywords:
Uremic toxins
Drug metabolism
UDP-glucuronosyltransferases
Mitochondria

ABSTRACT

During chronic kidney disease (CKD), drug metabolism is affected leading to changes in drug disposition. Furthermore, there is a progressive accumulation of uremic retention solutes due to impaired renal clearance. Here, we investigated whether uremic toxins can influence the metabolic functionality of human conditionally immortalized renal proximal tubule epithelial cells (ciPTEC) with the focus on UDP-glucuronosyltransferases (UGTs) and mitochondrial activity. Our results showed that ciPTEC express a wide variety of metabolic enzymes, including UGTs. These enzymes were functionally active as demonstrated by the glucuronidation of 7-hydroxycoumarin (7-OHC; K_m of 12±2 μM and a V_max of 76±3 pmol/min/mg) and p-cresol (K_m of 33±13 μM and a V_max of 266±25 pmol/min/mg). Furthermore, a wide variety of uremic toxins, including indole-3-acetic acid, indoxyl sulfate, phenylacetic acid and kynurenic acid, reduced 7-OHC glucuronidation with more than 30% as compared with controls (p<0.05), whereas UGT1A and UGT2B protein expressions remained unaltered. In addition, our results showed that several uremic toxins inhibited mitochondrial succinate dehydrogenase (SDH), i.e. complex II activity with more than 20% as compared with controls (p<0.05). Moreover, indole-3-acetic acid decreased the reserve capacity of the electron transport system with 18% (p<0.03). In conclusion, this study shows that multiple uremic toxins inhibit UGT activity and mitochondrial activity in ciPTEC, thereby affecting the metabolic capacity of the kidney during CKD. This may have a significant impact on drug and uremic retention site disposition in CKD patients.

© 2012 Elsevier B.V. All rights reserved.

1. Introduction

Renal function is an important aspect in drug clearance and it is widely known that drug disposition is altered in patients with chronic kidney disease (CKD)[1–3]. These changes in pharmacokinetics are partially due to a decreased glomerular filtration and tubular secretion. Another hallmark of CKD is the accumulation of potentially toxic solutes that are normally excreted via the urine. These uremic toxins can cause a multitude of pathologies, including renal fibrosis, anemia, bone disorders and cardiovascular disease[4,5]. Currently, more than 110 uremic toxins are known, divided into three distinct classes based on their physico-chemical properties: the small water-soluble compounds, the middle molecules and the protein-bound solutes[5,6]. The latter group of retention solutes are actively secreted by the healthy kidney and are difficult to eliminate using current dialysis strategies[7]. Since protein-bound uremic toxins accumulate during renal failure it could be argued that these compounds affect drug metabolism in CKD patients by interacting with renal enzymes. Many drugs commonly used in the clinic are metabolized by phase II enzymes, which catalyze conjugation reactions, including sulfation, acetylation and glucuronidation[8]. Several

Abbreviations: 7-OHC, 7-hydroxycoumarin; 7-OHCG, 7-hydroxycoumarin glucuronide; AA, antinymycin A; ciPTEC, conditionally immortalized human renal proximal tubule epithelial cells; CKD, chronic kidney disease; CMPP, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid; CBF, chronic renal failure; CYP, cytochrome p450; E, ETF, electron transport system; FCCP, p-trifluoromethoxy carbonyl cyanide phenyl hydrazone; FCS, fetal calf serum; GST, glutathione S-transferase; HA, hippocanic acid; HEG293, human embryonic kidney cells; HPLC, high-performance liquid chromatography; IIA, indole-3-acetic acid; IS, indoxyl sulfate; KA, kynurenic acid; LEAK, M, medium; MIC, uremic toxin mix; MITT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; NAT, N-acetyltransferase; ory, oligomycin A; OAT, organic anion transporter; Ox, oxalate; OXPHOS, oxidative phosphorylation; pC, p-cresol; PCG, p-cresyl glucuronide; Pcs, p-cresyl sulfate; PHA, phenylacetic acid; PHS, phenyl sulfate; PTEC, proximal tubule cells; Pu, putrescine; QA, quinolinic acid; R, ROUTINE, RGT, rotenone; RXD, residual oxygen consumption; SULT, sulfotransferase; UDPGA, UDP-glucuronic acid; UGT, UDP-glucuronosyltransferases; ZD-1, tight junction protein 1

* Corresponding author at: Department of Pharmacology and Toxicology, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, Geert Grooteplein 26–28, 6525 GA Nijmegen, The Netherlands. Tel.: +31 24 3613730; fax: +31 24 3614214.

E-mail address: r.masereeuw@pharmtox.umcn.nl (R. Masereeuw).

0925-4439/$ – see front matter © 2012 Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.bbadis.2012.09.006

Biochimica et Biophysica Acta 1832 (2013) 142–150
Biochimica et Biophysica Acta
journal homepage: www.elsevier.com/locate/bbadis
studies demonstrated that the pharmacokinetics of drugs solely cleared via phase II metabolism is changed in CKD patients. For instance, a decreased glucuronidation of metoclopramide, chloramphenicol, p-aminobenzoic acid, zidovudine and morphine have been reported in patients with chronic renal failure (CRF) [9–14]. Moreover, the acetylation of isoniazid is reduced in CKD patients [15]. However, little information is available about the mechanism underlying the observed decrease in phase II metabolism during renal failure.

UDP-glucuronosyltransferases (UGT) are an important class of phase II enzymes that catalyze the conjugation of glucuronic acid to many xenobiotics, environmental pollutants and endogenous compounds [16,17]. Next to drugs, uremic retention solutes are also prone to glucuronidation, and at least two glucuronides have been identified in uremic biological fluids, p-cresyl glucuronide and indoxyl glucuronide [18–20]. UGTs are expressed in several organs including the liver, gastrointestinal tract and kidney, and to date 19 human UGT proteins have been identified [21,22]. Due to the relative abundance of the essential cofactor UDP-glucuronic acid (UDPGA), glucuronidation is the most prevalent conjugation reaction and under normal metabolic conditions, the supply of UDPGA is not rate-limiting for this process [23]. Yet, during excessive glucogenesis or altered redox conditions, UGT activity is impaired [23,24]. After the liver, UGT activity is highest in the kidney, emphasizing the pivotal role of this organ in facilitating xenobiotic clearance via glucuronidation [8,25]. Previously, Yu et al. demonstrated that UGT expression and activity were down-regulated in the liver and kidney of 5/6 nephrectomized rats. However, this effect was also observed in control pair-fed rats and was possibly due to a decreased food intake [26]. Thus, the repercussions of CKD on UGT’s remain to be elucidated.

In the present study, conditionally immortalized human renal proximal tubule epithelial cells (ciPTEC) were used to investigate the impact of multiple uremic toxins on renal UGT activity. Our results show that ciPTEC express a broad array of drug metabolism enzymes, similar to human kidney. Furthermore, UGT proteins were functionally active in ciPTEC, as demonstrated by 7-hydroxycoumarin (7-OHC) and p-cresol glucuronidation. Uremic toxins inhibited the glucuronidation of 7-OHC without affecting UGT1A and UGT2B protein expression, indicating a reduction in enzyme activity. Moreover, exposure of ciPTEC to uremic toxins caused a reduction in mitochondrial succinate dehydrogenase activity and in the maximum capacity of the oxidative phosphorylation (OXPHOS) system, which could explain the observed inhibitory effect of uremic toxins on glucuronide formation. These results present a novel pathway via which uremic retention solutes affect the metabolic capacity of the kidney and are likely involved in altering drug metabolism by glucuronidation in CKD patients.

2. Materials and methods

2.1. Chemicals

All chemicals were obtained from Sigma (Zwijndrecht, The Netherlands) unless stated otherwise. Stock solutions of uremic toxins were prepared as described by Cohen et al. [27] and were stored at –20 °C. Both p-cresyl sulfate and phenyl sulfate were synthesized as a potassium salt as described previously [28]. P-cresyl glucuronide was produced from glucuronil-trichloroacetimidate and p-cresol, as described above, and then scanned using the iBlot dry blotting system (Invitrogen). Afterwards, the membrane was blocked using Odyssey Blocking Buffer, (1:1 diluted with PBS; LI-COR Biosciences, Lincoln, NE, USA) during 1 h at RT. The membrane was then incubated overnight at 4 °C with rabbit polyclonal UGT1A or UGT2B antibody (1:200; both Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Mouse monoclonal β-actin antibody (1:10,000; Sigma) was simultaneously incubated to serve as a protein loading control. Antibodies were diluted in Odyssey Blocking Buffer containing 0.1% (v/v) Tween-20. The secondary antibodies, goat-α-mouse Alexa Fluor 680 (1:20,000; Invitrogen) and goat-α-rabbit IRDye 800 (1:20,000; Rockland, Gilbertsville, PA, USA), were incubated for 1 h at RT in Odyssey Blocking Buffer containing 0.1% (v/v) Tween-20 and 0.01% (w/v) SDS. The membrane was thoroughly washed, as described above, and then scanned using the Odyssey Infrared Imaging System (LI-COR Biotechnology). Intensity of the protein bands was quantified using the Odyssey Application software version 2.1.

2.2. Cell culture

The ciPTEC line was generated as previously described by Wilmer et al. [30]. The cells were cultured in ciPTEC medium containing phenol red free DMEM/F12 medium (Gibco/Invitrogen, Breda, The Netherlands) supplemented with 10% (v/v) fetal calf serum (FCS; MP Biomedicals, Uden, The Netherlands), insulin (5 μg/ml), transferrin (5 μg/ml), selenium (5 ng/ml), hydrocortisone (36 ng/ml), epithelial growth factor (10 ng/ml), and tri-iodothyronine (40 μg/ml) at 33 °C in a 5% (v/v) CO2 atmosphere. Propagation of cells was maintained by subculturing the cells at a dilution of 1:3 to 1:6 at 33 °C. For experiments, cells were cultured at 33 °C to 40% confluence, followed by maturation for 7 days at 37 °C. Experiments were performed on the cells between passages 30 and 40.

2.3. Quantitative PCR array

To study the gene expression of drug metabolism enzymes, ciPTEC were cultured and differentiated cells (7 days at 37 °C) were harvested. Total RNA was isolated using an RNeasy Mini kit (Qiagen, Venlo, The Netherlands) according to the manufacturer’s recommendations. Subsequently, cDNA was generated using the Omniscript RT-kit (Qiagen) according to the manufacturer’s recommendations. Following cDNA synthesis, RT2 Profiler PCR arrays (drug metabolism: phase I and phase II enzymes; Qiagen) were performed according to the manufacturer’s recommendations, using a CFX96 Real-Time PCR detection system (Bio-rad, Veenendaal, The Netherlands). Quantification of gene expression was performed using the CFX96 system software (Bio-rad) and the web-based PCR array data analysis software (Qiagen). GAPDH was used as housekeeping gene, and relative expression levels were calculated as percentage as compared with GAPDH (100%).

2.4. Western blotting

To study the protein expression of UGT1A and UGT2B, ciPTEC were cultured and exposed to 0–2 mM of different uremic toxins for 48 h. After treatment, cells were harvested using RIPA buffer containing 1% (v/v) Igepal CA630, 0.5% (v/v) Nadeoxycholate, 0.1% (w/v) SDS, 0.01% (w/v) phenylmethane sulphonfluoride, 3% (v/v) aprotinin and 1 mM Na-orthovanadate. Total protein (50 μg) was separated via 10% (w/v) gels and blotted onto nitrocellulose membranes using the iBlot dry blotting system (Invitrogen). Afterwards, the membrane was blocked using Odyssey Blocking Buffer, (1:1 diluted with PBS; LI-COR Biosciences, Lincoln, NE, USA) during 1 h at RT. The membrane was then incubated overnight at 4 °C with rabbit polyclonal UGT1A or UGT2B antibody (1:200; both Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Mouse monoclonal β-actin antibody (1:10,000; Sigma) was simultaneously incubated to serve as a protein loading control. Antibodies were diluted in Odyssey Blocking Buffer containing 0.1% (v/v) Tween-20. Afterwards, the membrane was thoroughly washed three times during 10 min with PBS containing 0.1% (v/v) Tween-20. The secondary antibodies, goat-α-mouse Alexa Fluor 680 (1:20,000; Invitrogen) and goat-α-rabbit IRDye 800 (1:20,000; Rockland, Gilbertsville, PA, USA), were incubated for 1 h at RT in Odyssey Blocking Buffer containing 0.1% (v/v) Tween-20 and 0.01% (w/v) SDS. The membrane was thoroughly washed, as described above, and then scanned using the Odyssey Infrared Imaging System (LI-COR Biotechnology). Intensity of the protein bands was quantified using the Odyssey Application software version 2.1.

2.5. Confocal microscopy

Cellular localization of UGT1A and UGT2B proteins was investigated using confocal microscopy. ciPTEC were seeded on 12-well Corning Costar Transwell Permeable Supports (type 3460, Corning Costar, NY, USA). Before seeding, the supports were coated with 50 μg/ml collagen type IV for 2 h at 37 °C. Subsequently, supports were washed with HBSS buffer (Gibco) and cells were seeded at a density of 1.33 × 105 cells/cm². Following maturation, as described above, cells were washed with wash solution (4% (v/v) FCS in HBSS) and fixed for 5 min with 2% (w/v) paraformaldehyde in HBSS. Next, cells were permeabilized for 10 min in HBSS with 0.3% (v/v) Triton and aspecific epitopes were blocked for 30 min with blocking buffer (2% (v/v) FCS, 0.5% (w/v) bovine serum albumin and 0.1% (v/v) Tween-20 in HBSS). Subsequently, the cells were incubated overnight at 4 °C with rabbit polyclonal UGT1A or
UGT2B antibody (1:50 in blocking buffer, Santa Cruz Biotechnology) using dynamic conditions. Afterwards, cells were incubated for 30 min with the secondary antibody goat-α-rabbit Alexa568 (1:200, Molecular Probes, Invitrogen). Subsequently, c iPTEC were incubated for 1 h with a mouse monoclonal antibody against the tight junction protein ZO-1 (1:50 in blocking buffer, Invitrogen, CA, USA). Next, the cells were simultaneously incubated for 30 min with goat-α-mouse Alexa488 (1:200, Molecular Probes, Invitrogen) and DAPI nucleic acid stain (300 nm, Molecular Probes, Invitrogen). The slides were then mounted using Fluorescent Mounting Medium (DakoCytomation, Dako Netherlands b.v., Heverlee, Belgium). Between all incubation steps the cells were washed with wash solution. Fluorescence was examined using the Olympus FV1000 Confocal Laser Scanning Microscope (Olympus, UK) and images were captured using the Olympus software FV10-ASW version 1.7.

2.6. High-performance liquid chromatography (HPLC)

HPLC was used to measure UGT activity via the glucuronidation of 7-hydroxycoumarin (7-OCH), as described previously, and p-cresol. To determine enzyme kinetics, c iPTEC were exposed to 7-OCH or p-cresol dissolved in HBSS at 37 °C and 4 °C (as negative control) using different concentrations (0–500 μM) and different incubation times (0–5 h). When used, β-glucuronidase from Helix pomatia was added 1 h prior to incubation with 7-OCH (50 μM for 3 h). In addition, UGT activity was also determined following exposure to uremic toxins for 48 h. Following treatment, c iPTEC were incubated with 10 μM 7-OCH for 3 h at 37 °C. Before chromatography an aliquot of culture medium was collected and centrifuged at 12,000×g for 3 min and 50 μl of the supernatant was injected into the HPLC-system (Spectra-Physics Analytical, Spectrasystem SCM400). To measure 7-OCH and 7-OCH glucuronide (7-OCH-Glc) the HPLC was equipped with a C18 HPLC column (GraceSmart RP 18 5 μ 150×4.6 mm; Grace, Breda, The Netherlands). Separation was performed at a flow rate of 1 ml/min with eluent A (95% (v/v) H2O, 5% (v/v) methanol and 0.2% (v/v) acetic acid) and eluent B (50% (v/v) H2O, 49% (v/v) acetonitrile and 1% (v/v) tetrahydrofuran) under the following gradient conditions: 0–3 min, 80–100% eluent A; 3–8 min, 50% eluent A; 8–9 min, 50–80% eluent A; 9–14 min, 80% eluent A. The compounds were detected at a wavelength of 316/382 nm. For the detection of p-cresyl sulfate and p-cresyl glucuronide (7-OCHG), the HPLC was equipped with a C18 HPLC column (GraceSmart RP 18 5 μ 150×4.6 mm; Grace, Breda, The Netherlands). For the detection of p-cresyl sulfate and p-cresyl glucuronide, eluent A. The compounds were detected at a wavelength of 316/382 nm. For the detection of p-cresyl sulfate and p-cresyl glucuronide (7-OCHG), the HPLC was equipped with a C18 HPLC column (GraceSmart RP 18 5 μ 150×4.6 mm; Grace, Breda, The Netherlands).

2.7. 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay

Mitochondrial succinate dehydrogenase activity was assessed using the MTT assay. c iPTEC were cultured in a 96 well culture plate and exposed to 1 mM or 2 mM of uremic toxins for 48 h. Next, medium was removed and 20 μl preheated (37 ℃) MTT-solution (5 mg 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide/ml c iPTEC medium) was added and incubated for 4 h at 37 ℃. Afterwards, MTT-solution was removed, followed by the addition of 200 μl DMSO to dissolve produced formazan crystals. The extinction of the solution was measured at 570 nm using a Benchmark Plus Microplate Spectrophotometer (Bio-rad).

2.8. Flow cytometry

In this study, flow cytometry was used to study c iPTEC morphology and viability. Cells were cultured in 12-well culture plates and treated for 48 h with 2 mM of uremic toxins. After incubation, cells were harvested using trypsin-EDTA and centrifuged at 600 g during 5 min. Subsequently, supernatant was removed and the cell pellet was resuspended in 100 μl PBS containing 4% (w/v) paraformaldehyde and 0.1% (v/v) saponin followed by 10 min incubation on ice. Subsequently, samples were centrifuged (600×g for 5 min) and resuspended in 100 μl PBS. Samples were acquired on a BD FACSCalibur (Becton Dickinson, Breda, The Netherlands). Analysis was performed using FlowJo software (TreeStar, Ashland, USA), gating on live cells.

2.9. High-resolution respirometry

Cells were cultured in T25 culture flasks and treated for 48 h with 2 mM indole-3-acetic acid. Subsequently, cells were harvested using trypsin-EDTA and centrifuged at 1500 x g during 5 min. Afterwards, the supernatant was removed and the cell pellet was resuspended in c iPTEC medium to obtain a suspension of approximately 1×10⁶ cells/ml. Two milliliters of the cell suspension was used to measure cellular oxygen consumption. Oxygen consumption was measured at 37 ℃ using polarographic oxygen sensors in a two-channel Oxymat (Oroboros Instruments, Innsbruck, Austria) using an established protocol. The cells were allowed to respire at basal level for at least 10 min until the flux was stable, representing routine respiration (R). Next, leak respiration (L) was determined by addition of the specific mitochondrial ATP synthase inhibitor oligomycin A (omy; 2.5 μM). Then, maximal ETS capacity (E) was quantified using increasing concentrations of the mitochondrial uncoupler p-trifluoromethoxy carbonyl cyanide phenyl hydrazone (FCCP; 2.5 μM maximum concentration). Finally, nonmitochondrial respiration (ROX) was assessed by adding a maximal (0.5 μM) concentration of the specific mitochondrial complex I inhibitor rotenone (ROT) followed by the Complex III inhibitor antimycin A (AA; 2.5 μM).

2.10. Kinetic analysis and statistics

Statistics were performed using GraphPad Prism 5.02 via one-way analysis of variance (ANOVA) followed by Dunnett’s Multiple Comparison Test or an unpaired t test. Differences between groups were considered to be statistically significant when p<0.05. The software was also used to perform linear and nonlinear regression analysis (Michaelis–Menten) and correlation analysis (Spearman).

3. Results

3.1. Selection of uremic toxins

In our study, 13 uremic solutes were selected containing one water-soluble solute (oxalate, Ox) and 12 protein-bound solutes. The latter group contained 4 tryptophan metabolites (indoxyl sulfate, IS; indole-3-acetic acid, 13A; kynurenic acid, KA; and quinolinic acid, QA), six phenols (phenylacetic acid, PHA; phenyl glucuronide, PHG; phenyl sulfate, PHS; p-cresol, pC; p-cresyl sulfate, pCS; and p-cresyl glucuronide, pCG), one hippurate (hippuric acid, HA), and one polyamine (putrescine, Pu). Moreover, a mix of several uremic toxins (Mix) was used, consisting of putrescine, oxalate, indoxyl sulfate and p-toluene sulfonic acid, a previously described phenolic model compound (1:1:1:1). This specific mix was chosen because it contained different classes of solutes, of which the stock solutions were all prepared in the same solvent (e.g. milli-Q).
3.2. Expression and activity of UGT in ciPTEC

Extrahepatic glucuronidation occurs mainly in the kidney and UGT expression and activity were demonstrated in both human and rat primary proximal tubule cells [8,34,35]. We used a recently established human renal proximal tubule cell line, [30,36] in which phase I and phase II drug metabolism enzyme expression levels were studied, with an emphasis on the class of UGT enzymes. A complete overview of the drug metabolism enzyme gene expression in ciPTEC is provided in Fig. S1. This figure clearly demonstrates that ciPTEC express a broad range of drug metabolism enzymes, including cytochrome p450 (CYP), sulfotransferase (SULT) and glutathione S-transferase (GST) enzymes, next to members of the UGT family. Fig. 1A shows that the gene expression of 18 UGTs was detected in ciPTEC of which UGT1A1, 1A9, 2B7, 2B10 and 2B28 were most abundantly expressed compared with GAPDH, with a relative expression of 11%, 2143%, 16%, 145% and 9%, respectively. Furthermore, using Western blotting UGT1A and 2B family members were detected in ciPTEC, with the predicted molecular weight of the enzymes (approximately 68 kD; Fig. 1B-C). Protein expression of the enzymes was also demonstrated in human kidney lysates, whereas their expression was absent in human embryonic kidney (HEK293) cells. Glucuronidation occurs in the cytosol, and confocal microscopy demonstrated that both UGT1A and 2B enzymes exhibit cytosolic localization in ciPTEC (Fig. 1D-E). Moreover, expression of tight junction protein 1 (ZO-1) revealed that ciPTEC form tight monolayers and that the cells maintain their epithelial characteristics during culturing.

To determine whether the UGTs were enzymatically active, a glucuronidation assay was performed using 7-OHC as a substrate. A concentration-dependent formation of 7-OHCG glucuronide was observed (Fig. 2A), and curve fitting revealed an apparent \( K_m \) of 12 ± 2 μM and a \( V_{max} \) of 76 ± 3 pmol/min/mg. Glucuronidation was demonstrated to be linear up to 5 h (Fig. 2B). Furthermore, as depicted in Fig. 2A and 2B, 7-OHCG metabolism was completely absent at 4 °C, indicating enzyme-dependent conjugation. Glucuronidation of 50 μM 7-OHC was concentration-dependently inhibited by β-glucuronidase with an approximate IC\(_{50}\) value of 50 U/ml, as demonstrated in Fig. 2C.

3.3. Uremic toxins decrease UGT activity

Next, it was investigated whether exposure of ciPTEC to uremic toxins could influence 7-OHCG glucuronidation. Fig. 3 shows that a myriad of uremic toxins belonging to three different physico-chemical classes, viz. tryptophan metabolites, phenols and water-soluble compounds, concentration-dependently inhibited the glucuronidation of 7-OHCG. Kynurenic acid, indole-3-acetic acid, phenylacetic acid and a mixture of uremic toxins most potently inhibited UGT activity (Fig. 3A-C). At the highest concentration, these toxins decreased glucuronide formation by 52%, 44%, 36% and 50%, respectively. In addition, at the same concentration, indoxyl sulfate, phenyl sulfate, oxalate, putrescine and hippuric acid inhibited the formation of 7-OHCG by 32%, 30%, 16% and 32%, respectively. In contrast, quinolinic acid and phenyl glucuronide did not affect 7-OHCG metabolism.

A decline in enzyme activity is often secondary to a decrease in protein expression, therefore, the impact of uremic toxins on UGT expression was examined. Exposure of ciPTEC to none of the different toxins reduced UGT1A and UGT2B protein expression with more than 15%, with both tested concentrations, compared to control. A representative sample of toxins is shown in Fig. 4, and the other toxins in Fig. S2.

3.4. P-cresol metabolism and impact on glucuronidation

To further investigate the mode of inhibition, ciPTEC were exposed to p-cresol, which can be metabolized to both p-cresyl sulfate and p-cresyl glucuronide [37]. Fig. 5A shows that p-cresol is indeed conjugated to glucuronic acid in ciPTEC and a concentration-dependent formation of p-cresyl glucuronide is demonstrated with a calculated \( K_m \) of 33 ± 13 μM and a \( V_{max} \) of 266 ± 25 pmol/min/mg. In contrast, ciPTEC did not metabolize p-cresol to p-cresyl sulfate (data not shown), despite the expression of multiple sulfotransferases, the enzymes that catalyze sulfation reactions (Fig. S1). Furthermore, HPLC revealed that p-cresol inhibited 7-OHCG formation by 72% (Fig. 5B). Yet, both p-cresol metabolites also inhibited UGT activity with approximately 20%.

3.5. Uremic toxins inhibit mitochondrial metabolism

Reduction of MTT is mainly dependent on mitochondrial succinate dehydrogenase activity [38]. Our results indicate that the majority of the toxins tested (e.g. putrescine, oxalate, indoxyl sulfate) did not significantly decrease MTT reduction with more than 15% compared to control (Fig. S3). Yet, p-cresol, p-cresyl sulfate and p-cresyl glucuronide significantly reduced mitochondrial succinate dehydrogenase activity (Fig. 5C).
activity with 28%, 21% and 14%, respectively (Fig. 6A). In addition, the toxins that most potently inhibited UGT activity (i.e. indole-3-acetic acid, phenylacetic acid and a mixture of uremic toxins) also significantly decreased MTT reduction at the highest concentration by 28%, 26% and 33%, respectively. Moreover, we observed a significant correlation between the two parameters studied, with a calculated Spearman r of 0.69 (p < 0.005; Fig. 6B). Since the MTT assay is often used to study cell viability, we aimed to confirm that the observed correlation was not due to the induction of cell death by uremic toxins. Flow cytometry revealed that exposure of ciPTEC to the solutes that had the most pronounced impact on cellular and mitochondrial metabolism did not affect cell morphology nor the percentage of living cells as compared with untreated cells (Fig. S4).

3.6. Inhibition of mitochondrial respiration by indole-3-acetic acid

Mitochondrial succinate dehydrogenase plays an essential role in the electron transfer chain and the tricarboxylic acid cycle (i.e. citric acid cycle) [39]. Therefore, we investigated the impact of indole-3-acetic acid on the OXPHOS system, since this solute had the most profound effect on both 7-OHC glucuronidation and MTT reduction. High-resolution respirometry revealed that basal mitochondrial respiration (R; ROUTINE), electron transport that was not coupled to ATP production (L; LEAK) and non-mitochondrial respiration (ROX; residual oxygen consumption) was not compromised by indole-3-acetic acid (Fig. 7A–B), further supporting the impression that uremic toxins did not induce cell death in ciPTEC. In contrast, the maximum capacity of the electron transport system (E; ETS) was reduced from 221 ± 21 pmol/s · 10^6 cells in untreated cells to 182 ± 17 pmol/s · 10^6 cells in ciPTEC exposed to indole-3-acetic acid, indicating that treatment caused a reduction in the reserve capacity for energy production. Fig. 7C shows that exposure of the cells to indole-3-acetic acid resulted in a significantly increased netRoutine/ETS ratio, with a 1.3 fold change. This signifies that a higher proportion of the maximum capacity of the OXPHOS system is activated to drive ATP synthesis, and implies that ciPTEC exposed to uremic toxins have a limited ability to supply energy for other cellular processes, such as enzymatic activity.
Fig. 4. UGT1A and UGT2B protein expression is not affected by uremic toxins. UGT1A and UGT2B protein expression was studied via Western blot. Cells were exposed for 48 h to ciPTEC medium (gray bars), 1 mM (white bars) or 2 mM (black bars) of several uremic toxins. (A/C) Afterwards cells were lysed and proteins were separated via SDS/PAGE and blotted onto nitrocellulose membranes. Both UGT1A and UGT2B were detected at 68 kD. (B/D) Fluorescence of the specific protein bands was determined using the Odyssey Infrared Imaging System. Bars represent mean ± SEM of the UGT band intensities corrected for β-actin from 3 independent experiments. IS, indoxyl sulfate; M, medium; Mix, uremic toxic mix; Ox, oxalate; Pu, putrescine.

4. Discussion

This study reports for the first time that multiple uremic toxins directly inhibit the function of an important class of phase II drug metabolism enzymes, namely UGTs, in human renal proximal tubule cells. Our results showed that uremic toxin-induced UGT inhibition was independent of an effect on protein expression, and inhibition seemed to occur in both a competitive (e.g. p-cresol) and non-competitive fashion (e.g. p-cresyl sulfate). It is likely that most uremic solutes act as non-competitive inhibitors of UGT activity, since the majority of these compounds are end-products of endogenous metabolism.

To further unravel the mode of inhibition, mitochondrial respiration was studied and the results indicated that indole-3-actic acid reduced the reserve capacity of the electron transport system. This finding provides more insight into the mechanism by which uremic toxins possibly inhibit UGT activity. As stated before, glucuronide formation is dependent on the availability of UDPGA, the donor of the glucuronide moiety [23]. UDPGA is formed from UDP-glucose by UDP-glucose dehydrogenase using nicotinamide adenine dinucleotide (NAD+), a coenzyme that plays an important role in energy metabolism [40]. In the mitochondria, enzymes of the citric acid cycle reduce NAD+ to NADH. Subsequently, NADH is oxidized by complex I of the electron transport chain during OXPHOS-mediated ATP production, resulting in the conversion of NADH to NAD+. Therefore, we postulate that a reduction in the activity of the mitochondrial electron transport chain induced by uremic toxins, as demonstrated in this study, caused a drop in NAD+ levels and, consequently, led to depletion of UDPGA, thereby decreasing UGT-mediated metabolism.

De novo synthesis of NAD+ in mammals is dependent on tryptophan metabolism via the kynurenine pathway [40]. Dietary tryptophan is converted to kynurenine by tryptophan 2,3-dioxigenase and indoleamine 2,3-dioxigenase, which are both considered the rate-limiting steps in this pathway [40,41]. Kynurenine can, subsequently, be metabolized to kynurenic acid by kynurenine aminotransferase and, via several other enzymatic steps, to quinolinic acid [41]. The latter metabolite is used by quinolinic acid phosphoribosyltransferase to form NAD+. Interestingly, it is known that plasma tryptophan levels are significantly diminished in CKD patients [42]. Furthermore, Fukuwatari et al. reported that NAD (NAD+ + NADH) concentrations were decreased in the liver, kidney and blood of rats with adenine-induced renal failure [43]. Thus, it is likely that UDPGA levels are reduced in patients with CKD due to altered tryptophan metabolism, resulting in a reduced UGT activity.

To our knowledge, this is the first report to demonstrate the influence of uremic toxins on mitochondrial metabolism and respiration in human proximal tubule cells. Previously, Owada et al. demonstrated that indoxyl sulfate stimulated renal mitochondrial superoxide production in rats [44]. Dzurik et al. described that hippuric acid reduced ammonia production by P-dependent mitochondrial glutaminase in kidney homogenates of acidified rats [45]. Furthermore, using isolated rat liver mitochondria, Kitagawa revealed that p-cresol...
inhibited state 3 respiration without affecting oxidative phosphorylation [46]. Yet, p-cresol is no longer regarded as a uremic toxin, [37] and it remains to be elucidated whether its major metabolite, p-cresyl sulfate, has a similar impact on mitochondrial respiration. Additionally, Riegel et al. reported that treatment of hepatocytes with ultrafiltrates of patients treated with high-flux membrane dialyzer significantly diminished MTT reduction [47]. However, the effect correlated with an increased LDH release, a marker of cell injury, and the decrease in metabolic activity might have been due to hepatotoxicity. These findings, together with our current results, suggest that uremic toxins might directly influence mitochondrial activity in different organs.

The uremic toxin concentrations used in this study do not always reflect the plasma levels determined in CKD patients, for instance the highest concentration reported for kynurenic acid is 50 μM, whereas the maximal uremic concentration for hippuric acid and phenylacetic acid are 2.6 and 7.7 mM, respectively [48,49]. An overview of the maximal uremic concentrations of the solutes used in the present study are provided in Table S1, and for a detailed description of uremic toxin concentrations the interested reader is referred to reviews by the European Uremic Toxin Work Group [48,50].

Since UGTs are located in the cytosol, enzyme activity depends on the intracellular levels of substrates rather than substrate concentrations in the blood. Uptake of uremic toxins in renal proximal tubules is fairly well characterized and shown to be dependent on a wide variety of transport proteins. Both organic anion transporter (OAT) 1 and OAT3, as well as organic anion transporting polypeptide 4C1, play an important role in the tubular uptake of uremic toxins [51–54]. In addition, it has been demonstrated that the multi-ligand receptor megalin is involved in the endocytotic uptake of a specific group of uremic toxins, i.e. advanced glycation end products [55]. Previously, Masereeuw et al. demonstrated that methyl hippuric acids accumulate in the isolated perfused rat kidney during secretory transport [56,57]. They reported that 2-methyl hippuric acid levels were 175-times higher in renal tissue compared to the perfusate and 4-methyl hippuric acid concentrations were even 600-times higher. Thus, it is likely that intracellular uremic toxin concentrations are much higher than total plasma concentrations. Therefore, it is complicated to extrapolate our findings to the clinical situation.

The present study demonstrates that UGT1A1, 1A9, 2B7 and 2B28 are highly expressed in ciPTEC, which corroborates previous reports on proximal tubule cells [21,34]. Lash et al. described that primary human proximal tubule cells (PTEC) express UGT1A1, 1A6 and 2B7 on protein level [34]. Furthermore, they postulated that UGT2B7 is the major UGT isoform present in PTEC cells. In the study from Ohno and coworkers, gene expression was demonstrated for UGT1A5, 1A6, 1A7, 1A9, 2B4, 2B7 and 2B17 in human kidney tissue, and they reported that UGT1A9 and 2B7 were most abundantly expressed [21]. Next to
members of the UGT family, cPiTEC were currently demonstrated to have RNA expression of phase I enzymes, such as CYP3A4, CYP4A11, CYP2D6, that have previously been detected in primary PTEC by Lash et al. [34]. Additionally, the phase II enzymes GSTA4, GSTP, GSTT and SULT1A3 were demonstrated in our current study, as well as in primary PTEC. Taken together, cPiTEC have a similar phase I and phase II enzyme expression profile compared with primary PTEC, indicating that this cell line is a suitable model to study extrarenal drug metabolism. Together with the endogenous expression of renal influx and efflux drug transporters, previously described by our group, [30] these data demonstrate that human cPiTEC is a unique tool to study renal pharmacokinetics.

The majority of studies investigating the effect of renal failure on drug metabolism focused on CYP enzymes. For instance, Leblond et al. demonstrated that during CKD, both hepatic protein and gene expression of CYP2C11, CYP3A4 and CYP3A2 decreased in rats, which correlated with a decreased metabolism of aminopyrine and ethyromycin [58,59]. The same group also showed that 48 h exposure of HK-2 cells to serum from uremic rats decreased the protein expression of CYP3A1, suggesting a role for uremic toxins in this process [60]. Moreover, using rat liver microsomes, Sun et al. described that indoxyl sulfate and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) directly inhibited CYP3A-mediated metabolism of ethyromycin [61]. With regard to phase II drug metabolism, Simard et al. demonstrated that N-acetylationtransferase (NAT)1 and NAT2 expression decreased in the liver of CRF rats accompanied by a decrease in NAT2-mediated N-acetylation of p-amino benzoic acid [9]. Furthermore, expression of both NAT1 and NAT2 decreased in rat hepatocytes following exposure to uremic serum, possibly via the action of parathyroid hormone, a known uremic toxin [9]. Taken together, there is a clear impact of uremic solutes on both phase I and phase II drug metabolism.

Hepatic and renal transporters play an important role in xenobiotic handling. Previously, our group described that several uremic toxins, including hippuric acid and indoxyl sulfate, inhibited transport by two important renal efflux transporters, namely breast cancer resistance protein and multidrug resistance protein 4 [33]. Huang et al. showed that uremic plasma, obtained from rats with CRF, inhibited p-glycoprotein-mediated transport [62]. Moreover, it is demonstrated that CMPF and hippuric acid inhibited the uptake by the renal uptake transporter OAT3 [51]. The impact of uremic toxins on the functionality of multiple transporters in those reports, and the observation of enzyme activity described in this study, indicate that the altered drug disposition observed in CKD patients can be attributed, at least in part, to uremic retention solutes.

In the present study, renal glucuronidation was solely studied in vitro using the cPiTEC model, which could differ from in vivo metabolism. Generally, UGT activity is studied using microsomes isolated from the organ of interest; however, by using a complete cell model instead of microsomes, we were able to unravel the possible mechanism via which uremic toxins indirectly influence UGT functionality. Moreover, it is known that there are species differences in renal glucuronidation [63], which did not hamper our study since cPiTEC are of human origin. Another possible drawback of the present study is that we studied renal metabolism, while during CKD, xenobiotics are metabolized mainly in the liver and intestine. However, it is known that both renal and non-renal clearance are affected in CKD patients [14], therefore we postulate that our results uncovered a general mechanism via which uremic toxins can diminish both renal and non-renal UGT activity, irrespective of the tissue-specific UGT expression profiles [21].

A main feature of CKD is the dysfunction of multiple organs and alterations in xenobiotic elimination pathways, however, the pathophysiologic mechanism underlying these changes are not fully elucidated. In this study we demonstrated that a wide variety of uremic toxins, belonging to several physico-chemical classes, inhibited renal glucuronidation, most likely by reducing the reserve capacity of the energy-generating OXPHOS system. Our results provide additional insight into the widespread toxic effect of uremic solutes and depict a novel pathway via which uremic toxins impede renal metabolic function and may have a clinically significant impact on drug disposition in patients with CKD.

Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.bbadi.2012.09.006.

Disclosures
None.

Acknowledgements
This work was funded by the Dutch Kidney Foundation (grant number IK08.03). M.J.G. Wilmer was supported by a grant from the Dutch government to the Netherlands Institute for Regenerative Medicine (NIRM, grant no. FES0908) and J. Jansen received funding from the Bio-Medical Materials Institute (Project P3.01 BioKid), co-funded by the Dutch Ministry of Economic Affairs, Agriculture and Innovation. J.G. Hoenderop was supported by an EURYI award from the European Science Foundation. The authors would like to thank A. Bilos for excellent technical support regarding the HPLC measurements. In addition, we thank A.E.M. Seegers for assisting in the experimental work.

References


